Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp44159_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
Director’s Share Dealing
February 20, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that on February 19, 2014, Graham Hetherington, the Company’s Chief Financial Officer, sold 40,000 Ordinary Shares in the Company (“Shares”) at an average sale price of £33.34251. The Shares were sold on the London Stock Exchange.
Following the above transaction, Mr Hetherington holds 52,089 Shares.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX